A Critical Appraisal of Clinical Practice Guidelines for Pharmacological Treatments of Paroxysmal Nocturnal Hemoglobinuria

References (40)

1. 1 Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement [DOI]
2. 2 Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: what are they and which is better? [DOI]
3. 3 The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines [DOI]
4. 4 Paroxysmal nocturnal hemoglobinuria [DOI]
5. 5 Comparing interprofessional and interorganizational collaboration in healthcare: A systematic review of the qualitative research [DOI]
6. 6 Strategies for the implementation of clinical practice guidelines in public health: an overview of systematic reviews [DOI]
7. 7 Systematic reviews of clinical practice guidelines: a methodological guide [DOI]
8. 8 Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review [DOI]
9. 9 Systematic review of current guideline appraisals performed with the Appraisal of Guidelines for Research & Evaluation II instrument—a third of AGREE II users apply a cut-off for guideline quality [DOI]
10. 10 Clinical Practice Guidelines: Tools to Support High Quality Patient Care [DOI]
11. 11 How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future [DOI]
12. 12 Improving clinical practice guidelines with implementation science [DOI]
13. 13 Assessment of the quality of recommendations from 161 clinical practice guidelines using the Appraisal of Guidelines for Research and Evaluation–Recommendations Excellence (AGREE-REX) instrument shows there is room for improvement [DOI]
14. 14 Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria [DOI]
15. 15 Pegcetacoplan for paroxysmal nocturnal hemoglobinuria [DOI]
16. 16 European clinical practice guidelines on the use of chemotherapy for advanced oesophageal and gastric cancers: a critical review using the AGREE II and the AGREE-REX instruments [DOI]
17. 17 How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry [DOI]
18. 18 Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician’s guide [DOI]
19. 19 Pesg PNH diagnosis, follow-up and treatment guidelines.
20. 20 A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument [DOI]
21. 21 Methodological Rigor and Transparency in Clinical Practice Guidelines for Nutrition Care in Critically Ill Adults: A Systematic Review Using the AGREE II and AGREE-REX Tools [DOI]
22. 22 Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up [DOI]
23. 23 Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase III PEGASUS study [DOI]
24. 24 Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations [DOI]
25. 25 A systematic review and critical appraisal of guidelines and their recommendations for sedation interruptions in adult mechanically ventilated patients [DOI]
26. 26 Consenso español para el diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna [DOI]
27. 27 AGREE‐S: AGREE II extension for surgical interventions – United European Gastroenterology and European Association for Endoscopic Surgery methodological guide [DOI]
28. 28 Diagnóstico y tratamiento de la hemoglobinuria paroxística nocturna [DOI]
29. 29 Quality assessment of clinical practice guidelines for neonatal sepsis using the Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument: A systematic review of neonatal guidelines [DOI]
30. 30 Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes [DOI]
31. 31 Clinical practice guidelines for frailty vary in quality but guide primary health care: a systematic review [DOI]
32. 32 Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool [DOI]
33. 33 Bridging Trial and Decision: A Checklist to Frame Health Technology Assessments for Resource Allocation Decisions [DOI]
34. 34 What information can we gain from the quality appraisal of guidelines with physical activity recommendations for cancer patients?A systematic review using the AGREE II and AGREE-REX tools [DOI]
35. 35 Quality of 2019 American optometric association clinical practice guideline for diabetic eye care [DOI]
36. 36 Efficacy and safety of current treatments for paroxysmal nocturnal hemoglobinuria: A systematic review [DOI]
37. 37 Quality assessment of clinical practice guidelines on psychological distress of cancer patients using the AGREE II instrument [DOI]
38. 38 Knowledge, lost in translation [DOI]
39. 39 Mexican consensus on the treatment of the paroxysmal nocturnal hemoglobinuria
40. 40 Technological and Patent Evolution of Murine Monoclonal Antibodies [DOI]

Cited by 0

No indexed citations yet.

Related research

• Central Retinal Vein Occlusion Secondary to Paroxysmal Nocturnal Hemoglobinuria — shares topic coverage
• Production of Monoclonal Specific Antibody against Brazzein Fusion Protein — shares topic coverage
• Immunoexpression of Mutated BRAF V600E Protein in Papillary Thyroid Carcinoma — shares topic coverage
• Dostarlimab: A Review of Its Pharmacology and Clinical Use in Management of Cancer — shares topic coverage
• Mathematical Model of Colorectal Cancer with Monoclonal Antibody Treatments — shares topic coverage